38
Views
2
CrossRef citations to date
0
Altmetric
Review

Novel methods to treat and prevent human papillomavirus infection

, &
Pages 593-600 | Published online: 10 Jan 2014

References

  • Harro CD, Pang Y-YS, Roden RBS et al. Safety and immunogenecity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst.93, 284–292 (2001).
  • Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0, IARC Press, Lyon, France (2004–2005).
  • Burd EM. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev.16, 1–17 (2003).
  • Jung W-W, Chun T, Sul D, Huang K-W et al. Strategies against human papillomavirus and cervical cancer. J. Microbiol.42(4), 255–266 (2004).
  • Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189(1), 12–19 (1999).
  • Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine24(Suppl. 1), S1–S15 (2006).
  • Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J. Natl Cancer Inst.87, 796–862 (1995).
  • Munoz N, Bosch FX, de Sanjose S et al. Epidimiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348, 518–527 (2003).
  • Roden RBS, Ling M, Wu T-C. Vaccination to prevent and treat cervical cancer. Hum. Pathol.35(8), 971–982 (2004).
  • Moscicki AB, Shiboski S, Broering J et al. The natural history of human papillomavirus as measured by repeated DNA testing in adolescent and young women. J. Pediatr.132, 277–284 (1998).
  • zur Hausen H. Papillomavirus and cancer: from basic studies to clinical application. Nature Rev. Cancer2, 342–350 (2002).
  • Syrjänen SM, Syrjänen KJ. New concepts on the role of human papillomavirus in cell cycle regulation. Ann. Med.31, 175–187 (1999).
  • Thomas M, Pim D, Banks L. The role of the E6–p53 interaction in the molecular pathogenesis of HPV. Oncogene1, 7690–7000 (1999).
  • Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J. Clin. Virol.32(1), 72–81 (2005).
  • Cubie HA, Seager AL, Beattie GJ et al. A longitudinal study of HPV detection and cervical pathology in HIV infected women. Sex. Transm. Infect.76, 257–261 (2000).
  • Frisch M, Biggar R, Goedert J. Human papillomavirus associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J. Natl Cancer Inst.92, 1500–1510 (2000).
  • Seshadri L, George S, Vasudevan B, Krishna S. Cervical intraepithelial neoplasia and human papillomavirus infection in renal transplant recipients. Indian J. Cancer38, 92–95 (2001).
  • Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist10(7), 528–538 (2005).
  • Campion M. Preinvasive disease. In: Practical Gynecologic Oncology, 3rd Edition. Berek J, Hacker N (Eds). Lippincott, Williams and Wilkins, PA, USA,271–344 (2000).
  • Sadler L, Saftlas A, Wang W et al. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA291(17), 2100–2106 (2004).
  • Crane JM. Pregnancy outcome after loop electrosurgical excision procedure: a systematic review. Obstet. Gynecol.102, 1058–1062 (2003).
  • Mao C, Koutsky LA, Ault K et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. Obstet. Gynecol.107(1), 18–27 (2006).
  • Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med.347(21), 1645–1651 (2002).
  • Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against CRPV infection. J. Virol.69, 3959–3963 (1995).
  • Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA92, 11553–11557 (1995).
  • Kirnbauer R, Chandrachaud LM, O’Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology219, 37–44 (1996).
  • Nardelli-Haefliger D, Wirthner D, Schiller J et al. Antibody responses in cervical secretions of female volunteers after intramuscular vaccination with purified HPV 16 VLPs. Proceedings of the 19th International Papillomavirus Conference. Sao Paulo, Brazil, September 1–7, 1–52 (2001).
  • Harro CD, Pang Y-Y, Roden RB et al. Safety and immunogenecity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst.93, 284–292 (2001).
  • Evans TG, Bonnez W, Rose RC et al. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis.183, 1485–1493 (2001).
  • Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364, 1757–1765 (2004).
  • Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol.6, 495–524 (1995).
  • Vogel FR. Improving vaccine performance with adjuvants. Clin. Infect. Dis.30(Suppl. 3), 266–270 (2000).
  • Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med.347, 1652–1661 (2002).
  • Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol.6(5), 271–278 (2005).
  • Muller M, Zhou J, Reed T et al. Chimeric papillomavirus-like particles. Virology234, 93–111 (1997).
  • Greenstone H, Nieland J, DeVisser K et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumour model. Proc. Natl Acad. Sci. USA95, 1800–1805 (1998).
  • Bell MC, Alvarez RD. Chemoprevention and vaccines: a review of the nonsurgical options for the treatment of cervical dysplasia. Int. J. Gynecol. Cancer15, 4–12 (2005).
  • Stoler MH, Rhodes CR, Whitbeck A et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol.23, 117–128 (1992).
  • Crook T, Morgenstern JP, Crawford L et al. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J.8, 513–519 (1989).
  • Zehbe I, Wilander E, Delius H et al. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res.58, 829–833 (1998).
  • Sheets EE, Urban RG, Crum CP et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol.188(4), 916–926 (2003).
  • Garcia F, Petry KU, Muderspach L et al. ZYC101a for treatment of high-grade cervical neoplasia: a randomized controlled trial. Obstet. Gynecol.103, 317–326 (2004).
  • Borysiewicz LK, Fiander A, NimakoM et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet347, 1523–1527 (1996).
  • Ressing ME, de Jong JH, Brandt RMP et al. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur. J. Immunol.29, 1292–1303 (1999).
  • Lacey CJ, Thompson HS, Monteiro EF et al. Phase IIa safety and immunogenecity of a therapeutic vaccine, TA-GW, in persons with genital warts. J. Infect. Dis.179, 612–618 (1999).
  • Thompson HS, Davies ML, Holding FP et al. Phase I safety and antigenecity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine17, 40–49 (1999).
  • van der Burg SH, Kwappenberg KM, O’Neill T et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV 16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine19, 3652–3660 (2001).
  • de Jong A, O’Neill T, Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2 E7E6 fusion protein vaccine. Vaccine20, 3456–3464 (2002).
  • Brown AK, Moore RG. HPV vaccines – why aren’t they the answer yet? Med. Health R I88(3), 74–79 (2005).
  • Chu NR, Wu HB, Wu T et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol.121, 216–225 (2000).
  • Hunt S. Technology evaluation: Hsp E7, StressGen Biotechnologies Corp. Curr. Opin. Mol. Ther.3, 413–417 (2001).
  • Kadish AS, Einstein MH. Vaccine strategies for human papillomavirus-associated cancers. Curr. Opin. Oncol.17(5), 456–461 (2005).
  • Einstein MH, Kadish AS, Burk RD et al. Heat shock protein (HSP) – based immunotherapy (HspE7) for treatment of CIN III. Gynecol. Oncol.96(3), Abstract 8, 909–1020 (2005).
  • Wang TL, Ling M, Shih I-M et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther.7, 726–733 (2000).
  • Santin AD, Hermonat PL, Ravaggi A et al. Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus types 16- and 18-positive cervical cancer. J. Virol.73, 5402–5410 (1999).
  • Ferrara A, Nonn M, Sehr P et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J. Cancer Res. Clin. Oncol.129, 521–530 (2003).
  • Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J. Biomed. Sci.5, 231–252 (1998).
  • Hallez S, Detremmerie O, Giannouli C et al. Interleukin-12-secreting human papillomavirus 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int. J. Cancer81, 428–437 (1999).
  • Bubenik J, Simova J, Hajkova R et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV16. Int. J. Oncol.14, 593–597 (1999).
  • Chang EY, Chen CH, Ji H et al. Antigen-specific cancer immunotherapy using a GM-CSF-secreting allogeneic tumor cell-based vaccine. Int. J. Cancer86, 725–730 (2000).
  • Diaz-Arrastia C, Arany I, Robazetti SC et al. Clinical and molecular responses in high-grade intraepithilial neoplasia treated with topical imiquimod 5%. Clin. Cancer Res.7, 3031–3033 (2001).
  • Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol.21, 1–14 (1999).
  • Miller RL. Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumours. Int. J. Dermatol.41, 3–6 (2002).
  • Munoz N, Bosch FX, Castellsaguet X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer111, 278–285 (2004).
  • Plummer M, Franceschi S. Strategies for human papillomavirus prevention. Virus Res.89, 285–293 (2002).
  • Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology13, 631–639 (2002).

Websites

  • CDC. Genital HPV Infection – CDC Fact Sheet. CDC (2004) www.cdc.gov/std/HPV/STDFact-HPV.htm
  • American Cancer Society. Cervical Cancer Fact Sheet (2005) www.cancer.org/downloads/PRO/CervicalCancer.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.